Therapeutic Advances in Rare Disease : Impact Factor & More
eISSN: 2633-0040
Open AccessShare this on:
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on Therapeutic Advances in Rare Disease
Therapeutic Advances in Rare Disease Journal Specifications
Indexed in the following public directories
Scopus 
DOAJ 
SJR
| Overview | |
| Publisher | SAGE Publishing |
| Language | English |
| Publication Time | 15 |
| Editorial Review Process | Blind peer review |
| General Details | |
| Language | English |
| Website URL | Visit website |
| Publication Details | |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY, CC BY-NC |
| OA statement | Visit website |
View less
Planning to publish in Therapeutic Advances in Rare Disease ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Therapeutic Advances in Rare Disease
Current therapeutic landscape of β-thalassemia: focus on gene therapy
- 28 Mar 2026
- Therapeutic Advances in Rare Disease
Reliability assessment using the test–retest method and minimal important changes in the Adult Fabry Disease Quality of Life Scale
- 1 Mar 2026
- Therapeutic Advances in Rare Disease
Challenges and opportunities for the use of telehealth in rare disease diagnosis, treatment, research, and education: key opinion leader interviews by the IRDiRC telehealth task force
- 1 Mar 2026
- Therapeutic Advances in Rare Disease
Could an outcome-based agreement be operationalized using real-world data from the Canadian Neuromuscular Disease Registry? Perspectives from an expert-led assessment in spinal muscular atrophy
- 1 Mar 2026
- Therapeutic Advances in Rare Disease
Patient and caregiver perspectives on neurodevelopmental and mental health care for RASopathies.
- 1 Mar 2026
- Therapeutic advances in rare disease
Miglustat: a first-in-class enzyme stabilizer for cipaglucosidase alfa for the treatment of late-onset Pompe disease.
- 1 Feb 2026
- Therapeutic advances in rare disease
Current therapeutic landscape of β-thalassemia: focus on gene therapy
- 28 Mar 2026
- Therapeutic Advances in Rare Disease
Reliability assessment using the test–retest method and minimal important changes in the Adult Fabry Disease Quality of Life Scale
- 1 Mar 2026
- Therapeutic Advances in Rare Disease
Challenges and opportunities for the use of telehealth in rare disease diagnosis, treatment, research, and education: key opinion leader interviews by the IRDiRC telehealth task force
- 1 Mar 2026
- Therapeutic Advances in Rare Disease
Could an outcome-based agreement be operationalized using real-world data from the Canadian Neuromuscular Disease Registry? Perspectives from an expert-led assessment in spinal muscular atrophy
- 1 Mar 2026
- Therapeutic Advances in Rare Disease
Patient and caregiver perspectives on neurodevelopmental and mental health care for RASopathies.
- 1 Mar 2026
- Therapeutic advances in rare disease
Miglustat: a first-in-class enzyme stabilizer for cipaglucosidase alfa for the treatment of late-onset Pompe disease.
- 1 Feb 2026
- Therapeutic advances in rare disease
FAQs on Therapeutic Advances in Rare Disease
How many articles did Therapeutic Advances in Rare Disease publish last year? 
Who is the publisher of Therapeutic Advances in Rare Disease?
